Larry W. Kwak

Larry W. Kwak

Auto-generated profile, based on publicly available information

Larry W. Kwak

Toni Stephenson Lymphoma Center, Beckman Research Institute, City of Hope, Duarte, CA

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2002 in Science
Verified
Journal Article
Closed access
PDF file
ABArya Biragyn
Arya Biragyn
PRPier Adelchi Ruffini
Pier Adelchi Ruffini
CLCynthia A. Leifer
Cynthia A. Leifer
EKElena Klyushnenkova
Elena Klyushnenkova
ASAlexander Shakhov
Alexander Shakhov
LKLarry W. Kwak
Larry W. Kwak
β-Defensins are small antimicrobial peptides of the innate immune system produced in response to microbial infection of mucosal tissue and skin. We demonstrate that murine β-defensin 2 (mDF2β) acts directly on immature dendritic cells as an endogenous ligand for Toll-like receptor 4 (TLR-4), inducing up-regulation of costimulatory molecules and dendritic cell maturation. These events, in turn, trigger robust, type 1 polarized adaptive immune responses in vivo, suggesting that mDF2β may play an important role in immunosurveillance against pathogens and, possibly, self antigens or tumor antigens.

1 June 2002 in Trends in Immunology
Verified
Journal Article
Closed access
DYDe Yang
De Yang
ABArya Biragyn
Arya Biragyn
LKLarry W Kwak
Larry W Kwak
JOJoost J Oppenheim
Joost J Oppenheim

1 October 1999 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MBMaurizio Bendandi
Maurizio Bendandi
CGChristopher D. Gocke
Christopher D. Gocke
CKCarol B. Kobrin
Carol B. Kobrin
FBFloyd A. Benko
Floyd A. Benko
LSLars A. Sternas
Lars A. Sternas
LKLarry W. Kwak
Larry W. Kwak

1 January 2014 in The Lancet Oncology
Verified
Journal Article
Closed access
JWJason R Westin
Jason R Westin
FCFuliang Chu
Fuliang Chu
MZMin Zhang
Min Zhang
LFLuis E Fayad
Luis E Fayad
LKLarry W Kwak
Larry W Kwak
SNSattva S. Neelapu
Sattva S. Neelapu

22 October 1992 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
LKLarry W. Kwak
Larry W. Kwak
MCMichael J. Campbell
Michael J. Campbell
DCDebra K. Czerwinski
Debra K. Czerwinski
SHSarah Hart
Sarah Hart
RMRichard A. Miller
Richard A. Miller
RLRonald Levy
Ronald Levy
The idiotypic determinants of the surface immunoglobulin of a B-cell lymphoma can serve as a clonal tumor-specific marker, which may have implications for immunotherapy. We sought to determine whether idiotype-specific immune responses against this autologous antigen could be induced in patients with B-cell lymphoma. Nine patients were selected who had minimal residual disease or a complete remission after chemotherapy. Each received a series of subcutaneous injections of the immunoglobulin derived from his or her tumor cells (immunoglobulin-idiotype protein), which had been conjugated to a protein carrier and mixed with an immunologic adjuvant. In seven of the nine patients the injections induced sustained idiotype-specific immunologic responses of the humoral type (two patients), the cell-mediated type (four patients), or both (one patient). The use of an adjuvant was essential for these immune responses. The induced antibodies bound specifically to autologous immunoglobulin idiotype, inhibited the binding of murine monoclonal antiidiotype antibodies, and bound autologous tumor cells. Cell-mediated responses were demonstrated by the specific proliferation of immune peripheral-blood mononuclear cells to the soluble immunoglobulin-idiotype protein in vitro. The tumors of both of the patients with measurable disease regressed completely. Toxicity associated with the vaccine was minimal and consisted only of mild reactions at the site of intramuscular injection. These results demonstrate that autologous immunoglobulin idiotype can be formulated into an immunogenic, tumor-specific antigen in humans with B-cell lymphoma, and they provide the background for large-scale trials of active specific immunotherapy of this disease. (N Engl J Med 1992;327:1209–15.)

1 June 1990 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
LKL W Kwak
L W Kwak
JHJ Halpern
J Halpern
ROR A Olshen
R A Olshen
SHS J Horning
S J Horning
While diffuse large-cell lymphoma (DLCL) is considered to be highly curable with current therapy, treatment failures are observed even with intensive combination chemotherapy regimens. In order to study the prognostic significance of actual dose intensity of chemotherapy in DLCL, we retrospectively analyzed 115 previously untreated patients treated as Stanford between 1975 and 1986 with cyclophosphamide, Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), vincristine, and prednisone (CHOP), methotrexate, bleomycin, Adriamycin, cyclophosphamide, vincristine, and dexamethasone ([M]BACOD), or methotrexate, Adriamycin, cyclosphosphamide, vincristine, prednisone, and bleomycin (MACOP-B). The actual relative dose intensity (RDI), the amount of drug actually administered to each patient during the first 12 weeks of therapy, was calculated as standardized to CHOP and analyzed in addition to clinical factors prognostic for survival by univariate analysis. Multivariate recursive partitioning (tree-structured) survival analysis identified the actual RDI of Adriamycin greater than 75% as the single most important predictor of survival. A model incorporating the actual RDI of Adriamycin and performance status, in combination with serum lactate dehydrogenase (LDH) and extranodal disease, defined three overall prognostic groups of patients with respective 3-year survival rates of 89%, 63%, and 18%. The three prognostic groups remained distinct, even when restricted to complete responders. This model was also predictive of survival when dose intensity was analyzed relative to the optimum dose defined for each of the three regimens and when applied to a subgroup of patients aged 50 years or younger. We conclude that actual RDI is an important prognostic factor for survival in DLCL and that analysis of RDI early in the course of treatment may allow modification of the treatment plan.